期刊文献+

高效液相色谱法测定多非利特胶囊的溶出度

Determination of the Dissolution of Dofetilide Capsules by HPLC
下载PDF
导出
摘要 目的:建立以高效液相色谱法测定多非利特胶囊溶出度的方法。方法:色谱柱为DiamonsilC18,流动相为水-甲醇(56∶44,用冰醋酸调pH至3.4),检测波长为229nm。按峰面积外标法计算浓度,并以小杯法测定溶出度。结果:多非利特浓度在1~51μg/ml范围内线性关系良好(r=0.9999,n=7),加样回收率为97.55%(RSD=0.14%),3批样品45min平均溶出度均在90%以上。结论:本方法操作简便、快捷,结果准确。 OBJECTIVE: To establish a HPLC method for the determination of the dissolution of dofetilide capsules METHODS: The separation was performed on Diamonsil-C18 column, with mobile phase consisted of water- methanol (56 : 44,with pH adjusted to 3.4 with glacial acetic acid) at a wavelength of 229nm. The concentration was computed using external reference method of peak area and the dissolution was determined by small cup method. RESULTS: The method showed a good linear relationship in the range of 1μg/ml-51μg/ml(r = 0.9 999, n = 7), the average recovery was 97,55% (RSD = 0.14%), the mean dissolutions at 45 minute of the 3 batches of samples were all above 90%. CONCLUSION : The method is simple, rapid and accurate.
作者 程佩素
出处 《中国药房》 CAS CSCD 北大核心 2006年第23期1822-1823,共2页 China Pharmacy
关键词 多非利特 高效液相色谱法 溶出度 Dofetilide HPLC Dissolution
  • 相关文献

参考文献3

  • 1Scott,Stern,张海澄,等.慢性心房纤颤的抗凝治疗[J].美国医学会杂志(中文版),2001,20(3):141-143. 被引量:1
  • 2Puererfellner,H.Recent developments in cardiovascular drug therapy:Treatment of atrial arrhythmias with new class Ⅲ drugs and beyond[J].Curr Med Chem Cardiovasc Hematol Agents,2004,2(1):79.
  • 3Tendera M,Wnuk-Wojnar AM,Graffo,et al.Efficacy and safety of dofetilide in the prevention of symptomatic episodes of paroxysmal supraventricular tachycardia:a 6-month double-blind comparison with propafenone and placebo[J].Am Heart J,2001,142(1):93.

二级参考文献14

  • 1Ezekowitz MD. Bridgers SL, James KE, et al, or the Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Investigator. Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. N Engl J Med. 1992;327:1406-1412.
  • 2Laupacis A, Albers G, Dalen J, Dunn MJ, Jacobsen AK. Singer DE. Antithrombotic therapy in atrial fibrillation. Chest 1998;114(9 suppl):5795-5885.
  • 3Stroke Prevention in Abial Fibrillation Investigators.Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: Stroke Prevention In Atrial Fibrllation II Study. Lancet 1994;3,43:687 -691.
  • 4Hart RG. Pearce LA, McBride R, Rothbart RM, Asinger RW, for the Stroke Prevention in Atrial Fibrillation (SPAF) Investigators. Factors associated with ischemic stroke during aspirin therapy in atrial fibrillation Stroke. 1999;30:1223-1229.
  • 5The SPAF III Writing Committee for the Stroke Prevention in Atrial Fibrillation Investigators. Patients with nonvalvular atrial fibrillation at low risk of stroke during treatment with aspirin: Stroke Prevention in Atrial Fibrillation III Study. JAMA, 1998;279:1273-1277.
  • 6Stollberger C, Chnupa P, Krollik G, et al. Transesophageal echocardiography to assess embolic risk in patients with atrial fibrillation. Ann Intern Med. 1998;128:630-638.
  • 7The Stroke Prevention in Atrial Fibrillation Investigators Committee on Echocardiography Transesophageal echocardlographic correlates of thromboembolism in high-risk patients with nonvalvular atrial fibrillation Ann Intern Med.1998.128:639-647
  • 8Ezekowitz MD, Levtne JA. preventing stroke in patients with atrial fibrillation. JAMA. 1999;281:1830-1835.
  • 9Hylek EM, Heiman H, Skates SJ, Sheehan MA,Singer DE. Acetaminophen and other risk factors for excessive warfarin anticoagulation. JAMA. 1998;279:657-662.
  • 10Laupacis A, Albers G, Dalen J, et al. Antithrombotic therapy in atrial fibrillation. Chest. 1995;108(Supp14):352S-359S.

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部